RECRUITING

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

Description

This study will be a 12-month prospective, genotype-blinded longitudinal observational study with current standard of clinical care. This study will enroll 100 pregnant women with OUD at UPMC Hospitals with its high volumes. Because of the observational nature of the study, the anticipated dropout rate will be ≤ 20%. Investigators expect the effective sample size of evaluable patients will be 200 with longitudinal data.

Study Overview

Study Details

Study overview

This study will be a 12-month prospective, genotype-blinded longitudinal observational study with current standard of clinical care. This study will enroll 100 pregnant women with OUD at UPMC Hospitals with its high volumes. Because of the observational nature of the study, the anticipated dropout rate will be ≤ 20%. Investigators expect the effective sample size of evaluable patients will be 200 with longitudinal data.

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

Condition
Opioid Use Disorder
Intervention / Treatment

-

Contacts and Locations

Pittsburgh

UPMC Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States, 15213

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Pregnant women with OUD and their infant
  • * Currently on BUP/METH for OUD
  • * Enrolled in prenatal opioid maintenance program
  • * Age \>18 years
  • * Singleton pregnancy
  • * Planned delivery at UPMC's Magee Womans Hospital
  • * Positive opioid urine screen results
  • * Serious maternal medical illness as deemed by the PI that would make it challenging to comply with study procedures
  • * HIV or AIDS
  • * Known major fetal congenital abnormalities

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ilana Hull,

Ilana Hull, MD, PRINCIPAL_INVESTIGATOR, Univrsity of Pittsburgh / UPMC Magee Womens Hospital

Study Record Dates

2025-12-01